Start here if you're new
what it is
Black Diamond is a biotech company trying to turn one brain-targeted cancer drug into approved treatments.
how it gets paid
Last year Black Diamond made n/a in revenue. license and collaboration revenue was the main engine at $70M, or 100% of sales.
what just happened
The latest print showed -$0.27 EPS on $70M revenue, and the market still cares more about 2026 data.
At a glance
C++ balance sheet — some cracks in the foundation
30/100 earnings predictability — expect surprises
6.7x trailing p/e — the market's not buying it — or you found a deal
-$1.27 fy2024 eps est
1.75 beta
xvary composite: 34/100 — weak
What they do
Black Diamond is a biotech company trying to turn one brain-targeted cancer drug into approved treatments.
You do not have a real moat yet. Black Diamond has 24 employees and 0 approved drugs, so the edge is still a lab story, not customer lock-in. The only hard proof is its lead drug, silevertinib, which is built to reach the brain and is headed toward Phase 2 data in 2026. If that readout misses, the moat story dies.
How they make money
n/a
annual revenue
license and collaboration revenue
$70M
grant revenue
$0
interest income
$0
other income
$0
The products that matter
lead clinical program
silevertinib
phase 2 data expected Q2 2026
This is the asset the market cares about. With the whole company valued at $121M, one meaningful readout can matter more than months of trading noise.
the stock-moving asset
next pipeline asset
bdtx-4933
second program behind a $121M equity story
This matters because a one-asset biotech is fragile. In a $121M company, every added program buys you time and another shot on goal, even when the commercial picture is still thin.
backup, not proof
Key numbers
-$1.27
fy2024 eps est
n/a
fy rev est
6.7x
trailing p/e
n/a
dividend yield
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $16M (12% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for BDTX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest print showed -$0.27 EPS on $70M revenue, and the market still cares more about 2026 data.
This is a clinical-stage stock, so the quarter matters less than the next catalyst. Yahoo Finance shows trailing EPS of $0.32, while the latest reported quarter missed at -$0.27, which tells you the accounting noise is real.
$70M
revenue
$0.27
eps
n/a
n/a
the number that mattered
The -$0.27 EPS print mattered most because it shows the company still depends on future data, not current profits.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Black Diamond's top risk is silevertinib Phase 2 disappointment in Q2 2026. In this stock, the lead program is not just important. It is the valuation framework.
high
trial data slips
Your stock lives on silevertinib data. VL says FDA feedback is due in the first half of 2026, and that timing matters more than any spreadsheet.
A bad 2026 readout could cut the stock by 40% to 60%.
high
single-asset exposure
One lead clinical-stage program carries most of the story. That is cleaner than a portfolio, but it also means one miss can break the thesis.
A failed program could threaten most of the $121M equity story.
med
cash burn risk
gives the balance sheet a C++ and risk rank 4. That is not collapse territory, but it is not comfort either.
More dilution could shave 10% to 25% off per-share value.
The whole setup depends on one 2026 catalyst. If silevertinib works, the stock gets a story. If it does not, you get a small biotech with a $121M market cap and no cushion.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
Q2 2026 Phase 2 silevertinib data
This is the date that matters. If the data is strong, a $121M valuation can look too low in a hurry. If the data misses, the $9.29 target math stops carrying weight.
risk
funding need in 2026
The snapshot already points you here. Watch the terms, not just the headline. Cheap capital buys time. Punitive capital transfers value away from current holders.
trend
market price versus analyst belief
The stock is $2.41 and the average target is $9.29. That spread is not comfort. It is evidence that this name is deeply disputed.
metric
price stability 5 / 100
Low stability tells you the tape can move harder than the facts you can observe between updates. Position discipline matters more here than in a normal stock.
Analyst rankings
earnings predictability
30 / 100
in human-speak, analysts do not see a stable earnings story here — expect estimate changes and surprise risk.
balance sheet grade
C++
Below average. Translation: the company has less room to absorb delays, setbacks, or expensive funding.
price stability
5 / 100
That is extremely low. This behaves more like a catalyst contract than a calm stock chart.
risk rank
4
Safer than only 20% of stocks in the dataset. You are not getting paid for safety here. You are paying for optionality.
source: institutional data
Institutional activity
institutional ownership data for BDTX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive